Literature DB >> 10952600

Enhanced reduction of Helicobacter pylori load in precolonized mice treated with combined famotidine and urease-binding polysaccharides.

F C Icatlo1, N Kimura, H Goshima, Y Kodama.   

Abstract

The present study investigated the effect of a model urease-binding polysaccharide in combination with a histamine H(2) receptor antagonist on Helicobacter pylori colonization in vivo. Euthymic hairless mice were treated daily with dextran sulfate via drinking water and/or famotidine via intragastric gavage starting at 1 week postchallenge with a CagA(+) VacA(+) (type 1) strain of H. pylori. Treatment of precolonized mice for 2 weeks with dextran sulfate combined with famotidine yielded a group mean bacterial load (per 100 mg of gastric tissue) of log(10) 1.04 CFU, which was significantly lower than those of the famotidine (log(10) 3.35 CFU, P < 0.01) and dextran sulfate (log(10) 2.45 CFU, P < 0.05) monotherapy groups and the infected nontreated group (log(10) 3.64 CFU, P < 0.01). Eradication was achieved after 2 weeks of treatment in 50% or more of the test mice using drug combinations (1 or 2 weeks of famotidine plus 2 weeks of dextran sulfate) versus none in the monotherapy and positive control groups. The enhanced activity of the drug combination may be related to the daily pattern of transient acid suppression by famotidine inducing periodic bacterial convergence to superficial mucus sites penetrated by dextran sulfate from the lumen. Increased urease-dextran sulfate avidity was observed in vitro in the presence of famotidine and may partly account for the enhanced activity. With potential utility in abbreviating treatment time and eradication of antibiotic-resistant strains, the use of urease-targeted polysaccharides concurrently with a gastric acid inhibitor warrants consideration as an additional component of the standard multidrug chemotherapy of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952600      PMCID: PMC90090          DOI: 10.1128/AAC.44.9.2492-2497.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Epi-fluorescence microscopy and image analysis used to measure diffusion coefficients in gel systems.

Authors:  B T Henry; J Adler; S Hibberd; M S Cheema; S S Davis; T G Rogers
Journal:  J Pharm Pharmacol       Date:  1992-07       Impact factor: 3.765

2.  [The effects of famotidine and omeprazole on 24-hour intragastric pH of normal subjects].

Authors:  S Ohara; M Hongo; S Asaki; A Sato; D Shibuya; H Sato; T Motojima; N Yamaguchi; T Ohara; T Tamura
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1988-07

3.  [An autoclavable stainless steel isolator for small scale gnotobiotic experiments (author's transl)].

Authors:  K Itoh; A Ozaki; T Yamamoto; T Mitsuoka
Journal:  Jikken Dobutsu       Date:  1978-01

Review 4.  NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease.

Authors: 
Journal:  JAMA       Date:  1994-07-06       Impact factor: 56.272

5.  Identical 24-hour intragastric pH response to low continuous infusion doses of famotidine in active gastric ulcer patients.

Authors:  V R Espitia; K Yamaoka; J Tanaka; T Kisu
Journal:  Intern Med       Date:  1992-03       Impact factor: 1.271

6.  Influence of pH on metabolism and urease activity of Helicobacter pylori.

Authors:  M Rektorschek; D Weeks; G Sachs; K Melchers
Journal:  Gastroenterology       Date:  1998-09       Impact factor: 22.682

Review 7.  The epidemiology of Helicobacter pylori infection.

Authors:  D N Taylor; M J Blaser
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

8.  Hydrogen ion concentration in the mucus layer on top of acid-stimulated and -inhibited rat gastric mucosa.

Authors:  C Schade; G Flemström; L Holm
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

9.  The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.

Authors:  S Lanzon-Miller; R E Pounder; S G Ball; D J Dalgleish; J Coward; A O Jackson
Journal:  Scand J Gastroenterol       Date:  1988-03       Impact factor: 2.423

Review 10.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

Authors:  J H Walsh; W L Peterson
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

View more
  2 in total

1.  Effectiveness of Cyanothece spp. and Cyanospira capsulata exocellular polysaccharides as antiadhesive agents for blocking attachment of Helicobacter pylori to human gastric cells.

Authors:  F Ascencio; N L Gama; R De Philippis; B Ho
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

2.  Effect of Acid Suppressants on Non-Helicobacter pylori Helicobacters Within Parietal Cells.

Authors:  Masahiko Nakamura; Futa Murasato; Anders Øverby; Yosuke Kodama; Hirofumi Michimae; Kazuki Sasaki; Bram Flahou; Freddy Haesebrouck; Somay Y Murayama; Shinichi Takahashi; Masayuki Uchida; Hidekazu Suzuki; Hidenori Matsui
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.